Welcome to the Emerging and Pandemic Infections Consortium
Welcome to EPIC – the Emerging and Pandemic Infections Consortium.
EPIC partners play an integral role in infectious disease research, from work that controlled diphtheria and helped eradicate smallpox 100 years ago, to current research in antimicrobial resistance and infection control.
Today, our collective fight against infectious threats, including COVID-19, highly pathogenic avian influenza and mpox, makes clear that there’s never been a more important time to advance EPIC – the Emerging and Pandemic Infections Consortium as a critical hub in the pan-Canadian effort to combat future pandemics.
Building on our momentum in combatting the SARS-CoV-2 virus, EPIC will marshal the advanced research infrastructure and the world-renowned research and training expertise of the EPIC partners to allow an integrated innovative response to infectious diseases.
EPIC is a collaborative initiative among:
- University of Toronto
- The Hospital for Sick Children (SickKids)
- Lunenfeld-Tanenbaum Research Institute
- Sunnybrook Research Institute
- University Health Network
- Unity Health Toronto
These globally-leading institutions will make a difference to preventing the next pandemic and enhancing the impact of the life sciences ecosystem in Ontario.
These are the four pillars of EPIC’s work
Toronto High Containment Facility
Toronto’s only Combined Containment Level 3 (C-CL3) facility for the study of human and animal pathogens has been critical to understanding the viral pathogens and developing therapeutics and treatments. Infectious diseases continue to pose a threat to Canadians’ health and prosperity. Investments in the facility will prepare Ontario and Canada for future pandemics.
Training & Talent
EPIC offers immersive and cross-disciplinary training to a diverse cohort of talent researching infectious diseases, who are ready to work in industry and academia. Hundreds of researchers, clinicians and lab staff will gain access to leading-edge technologies, develop the skills to turn discovery into solutions, and connect Canada to global networks of pandemic surveillance and response.
Transformative Research
EPIC will connect multiple disciplines to address infectious diseases. Insights made possible by state-of-the-art platforms that accelerate the discovery and production of therapies will combine with the expertise of clinicians, engineers, public health experts and scientists to translate treatments to patients and improve their outcomes.
Knowledge Translation
EPIC will play an important role as a knowledge broker. It will create a hub for potential commercialization of novel therapeutics. New researchers at EPIC will be equipped to explain bench science to decision-makers and the public, as well as to translate discoveries into made-in-Canada products and solutions to global health challenges.
EPIC News
Member Spotlight: Sarah Haines
For this month’s member spotlight, we caught up with Sarah Haines, an assistant professor in the department of civil and mineral engineering in the Faculty of Applied Science and Engineering. Sarah’s research is on building science and indoor environmental quality with a particular focus on indoor air quality and the indoor microbiome. We also talk about her work with Indigenous communities to improve housing and drinking water quality.
How worried should I be about Marburg? An expert Q&A with Rob Fowler
Earlier this year, Equatorial Guinea declared its first outbreak of Marburg virus disease, with 11 confirmed deaths so far. The disease is caused by Marburg virus, which belongs to the same family of viruses as Ebola, and presents with similar symptoms including high fever, diarrhea, abdominal pain and cramping, and occasionally severe bleeding. For this expert Q&A, we sat down with Rob Fowler to talk about the recent Marburg outbreak, what lessons we can take away from Ebola and how our community can help.
U of T home to new hub that will strengthen Canada’s pandemic preparedness and increase biomanufacturing capacity
A new national hub focused on enhancing Canada’s ability to respond quickly, effectively and equitably to future pandemics has become a reality with $2 million in funding from the Canada Biomedical Research Fund. Led and anchored by the University of Toronto, the Canadian Hub for Health Intelligence and Innovation in Infectious Diseases (HI3) is a collaborative, multi-disciplinary and multi-sector coalition of over 80 partners. It will provide a powerful network to support a robust domestic pipeline of life-saving vaccines and therapeutics targeting existing and emerging infectious threats.
